<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2fd20fd5-f122-aa82-e063-6294a90a52a7"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use CIPROFLOXACIN AND DEXAMETHASONE OTIC SUSPENSION safely and effectively. See full prescribing information for CIPROFLOXACIN AND DEXAMETHASONE OTIC SUSPENSION.
 <br/>
      <br/>
CIPROFLOXACIN and DEXAMETHASONE otic suspension
 <br/>
Initial U.S. Approval: 2003
</title>
   <effectiveTime value="20250308"/>
   <setId root="2fd20fcb-222c-bd38-e063-6294a90ac9cd"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="828374897"/>
            <name>Redpharm Drug</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="828374897"/>
                        <name>Redpharm Drug</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" displayName="repack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="67296-1943" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="2fd228d8-74d0-2e53-e063-6394a90aa6c3"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250308"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="67296-1943" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Ciprofloxacin and dexamethasone</name>
                        <formCode code="C60995" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUSPENSION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ciprofloxacin and dexamethasone</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="72485-625" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R57ZHV85D4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Y27PUL9H56" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TYLOXAPOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q40Q9N063P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ACETIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4550K0SC9B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM ACETATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="T4V6TWG28D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYETHYL CELLULOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="3"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4BA73M5E37" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CIPROFLOXACIN HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="5E8K9I0O4U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CIPROFLOXACIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7S5I7G3JQL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXAMETHASONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="7S5I7G3JQL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXAMETHASONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="8" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, DROPPER"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="67296-1943-8" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20231101"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA215768" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231101"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38192" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="AURICULAR (OTIC)"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="2fd20f90-86f7-f0d4-e063-6394a90aae9e"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension USP is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Acute Otitis Externa (AOE) in pediatric (age 6 months and older), adult and elderly patients due to
  
   <content styleCode="italics">Staphylococcus aureus</content>and
  
   <content styleCode="italics">Pseudomonas aeruginosa</content>.
 
  </item>
                  </list>
               </text>
               <effectiveTime value="20231101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension is a combination of ciprofloxacin, a fluoroquinolone antibacterial and dexamethasone, a corticosteroid, indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Acute Otitis Externa (AOE) in pediatric (age 6 months and older), adult, and elderly patients due to
  
     <content styleCode="italics">Staphylococcus aureus</content>and
  
     <content styleCode="italics">Pseudomonas aeruginosa</content>. (1)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="2fd20f90-86f8-f0d4-e063-6394a90aae9e"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20231101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension is for otic use (ears) only, not for ophthalmic use, or for injection. (2.1)</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Shake well immediately before use. (2.1)</item>
                           <item>Instill four drops into the affected ear twice daily, for seven days. (2.2)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="2fd20f90-86f9-f0d4-e063-6394a90aae9e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Administration Instructions</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension is for otic use (ears) only, and not for ophthalmic use, or for injection.</item>
                           <item>Shake well immediately before use.</item>
                        </list>
                     </text>
                     <effectiveTime value="20231101"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="2fd20f90-86fa-f0d4-e063-6394a90aae9e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosage</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">For the Treatment of Acute Otitis Externa (age 6 months and older)</content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>The recommended dosage regimen is as follows:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Four drops [equivalent to 0.14 mL of ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension, (consisting of 0.42 mg ciprofloxacin and 0.14 mg dexamethasone)] instilled into the affected ear twice daily for seven days.</item>
                           <item>The suspension should be warmed by holding the bottle in the hand for one or two minutes to avoid dizziness, which may result from the instillation of a cold suspension.</item>
                           <item>The patient should lie with the affected ear upward, and then the drops should be instilled.</item>
                           <item>This position should be maintained for 60 seconds to facilitate penetration of the drops into the ear canal. Repeat, if necessary, for the opposite ear.</item>
                           <item>Discard unused portion after therapy is completed.</item>
                        </list>
                     </text>
                     <effectiveTime value="20231101"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="2fd20f90-86fb-f0d4-e063-6394a90aae9e"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Otic Suspension: Each mL of ciprofloxacin and dexamethasone otic suspension USP contains ciprofloxacin hydrochloride, USP 0.3% (equivalent to 3 mg ciprofloxacin base) and dexamethasone, USP 0.1% equivalent to 1 mg dexamethasone.</paragraph>
               </text>
               <effectiveTime value="20231101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Otic Suspension: Each mL of ciprofloxacin and dexamethasone otic suspension USP contains ciprofloxacin hydrochloride 0.3% (equivalent to 3 mg ciprofloxacin base) and dexamethasone 0.1% (equivalent to 1 mg dexamethasone). (3)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="2fd20f90-86fc-f0d4-e063-6394a90aae9e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to other quinolones, or to any of the components in this medication.</item>
                     <item>Use of this product is contraindicated in viral infections of the external canal, including herpes simplex infections and fungal otic infections.</item>
                  </list>
               </text>
               <effectiveTime value="20231101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to other quinolones, or to any of the components in this medication. (4)</item>
                           <item>Use of this product is contraindicated in viral infections of the external canal, including herpes simplex infections and fungal otic infections. (4)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="2fd20f90-86fd-f0d4-e063-6394a90aae9e"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20231101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Hypersensitivity and anaphylaxis have been reported with systemic use of quinolones. Discontinue use if this occurs with use of ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension. (5.1)</item>
                           <item>Prolonged use may result in overgrowth of non-susceptible bacteria and fungi. (5.2)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.1">
                     <id root="2fd20f90-86fe-f0d4-e063-6394a90aae9e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolones. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal, or facial edema), airway obstruction, dyspnea, urticaria, and itching.</paragraph>
                     </text>
                     <effectiveTime value="20231101"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="2fd20f90-86ff-f0d4-e063-6394a90aae9e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Potential for Microbial Overgrowth with Prolonged Use</title>
                     <text>
                        <paragraph>Prolonged use of ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension may result in overgrowth of non-susceptible, bacteria and fungi. If the infection is not improved after one week of treatment, cultures should be obtained to guide further treatment. If such infections occur, discontinue use and institute alternative therapy.</paragraph>
                     </text>
                     <effectiveTime value="20231101"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="2fd20f90-8700-f0d4-e063-6394a90aae9e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Continued or Recurrent Otorrhea</title>
                     <text>
                        <paragraph>If otorrhea persists after a full course of therapy, or if two or more episodes of otorrhea occur within six months, further evaluation is recommended to exclude an underlying condition, such as cholesteatoma, foreign body, or a tumor.</paragraph>
                     </text>
                     <effectiveTime value="20231101"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="2fd20f90-8701-f0d4-e063-6394a90aae9e"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious adverse reactions are described elsewhere in the labeling:</paragraph>
                  <br/>
                  <list listType="unordered" styleCode="Disc">
                     <item>Hypersensitivity Reactions
  
   <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>
                     </item>
                     <item>Potential for Microbial Overgrowth with Prolonged Use
  
   <content styleCode="italics">[see Warnings and Precautions (5.2)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20231101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions were ear discomfort (3%), ear pain (2.3%), and ear pruritus (1.5%). (6)</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Sentiss at 1-855-473-6847 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_6.1">
                     <id root="2fd20f90-8702-f0d4-e063-6394a90aae9e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>In Phases II and III clinical trials, a total of 537 patients were treated with ciprofloxacin and dexamethasone otic suspension with AOE. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Acute Otitis Externa</content>
                        </paragraph>
                        <paragraph>The following adverse reactions occurred in 0.4% or more of the patients with intact tympanic membranes.</paragraph>
                        <paragraph/>
                        <table width="567.777" cellspacing="0" cellpadding="0">
                           <col width="50%"/>
                           <col width="50%"/>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Adverse Reactions</content>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Incidence (N=537)</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Ear pruritus</td>
                                 <td styleCode="Rrule" valign="top">1.5%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Ear debris</td>
                                 <td styleCode="Rrule" valign="top">0.6%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Superimposed ear infection</td>
                                 <td styleCode="Rrule" valign="top">0.6%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Ear congestion</td>
                                 <td styleCode="Rrule" valign="top">0.4%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Ear pain</td>
                                 <td styleCode="Rrule" valign="top">0.4%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">Erythema</td>
                                 <td styleCode="Rrule" valign="top">0.4%</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The following adverse reactions were each reported in a single patient: ear discomfort; decreased hearing; and ear disorder (tingling).</paragraph>
                     </text>
                     <effectiveTime value="20231101"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="2fd20f90-8703-f0d4-e063-6394a90aae9e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post approval use of ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reactions include auricular swelling, headache, hypersensitivity, otorrhea, skin exfoliation, rash erythematous, and vomiting.</paragraph>
                     </text>
                     <effectiveTime value="20231101"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="2fd20f90-8704-f0d4-e063-6394a90aae9e"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20231101"/>
               <component>
                  <section ID="Section_8.1">
                     <id root="2fd20f90-8705-f0d4-e063-6394a90aae9e"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no available data on ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Because of the minimal systemic absorption of ciprofloxacin and dexamethasone following topical otic administration of ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension, this product is expected to be of minimal risk for maternal and fetal toxicity when administered to pregnant women
 
  <content styleCode="italics">[see Clinical Pharmacology (12.3)]</content>.

 </paragraph>
                        <paragraph>Animal reproduction studies have not been conducted with ciprofloxacin 0.3% and dexamethasone 0.1%otic suspension. Oral administration of ciprofloxacin during organogenesis at doses up to 100 mg/kg to pregnant mice and rats, and up to 30 mg/kg to pregnant rabbits did not cause fetal malformations (see Data). These doses were at least 200 times the recommended otic human dose (ROHD in mice, rats, and rabbits, respectively, based on body surface area (BSA). With dexamethasone, malformations have been observed in animal studies after ocular and systemic administration.</paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and of miscarriage is 15% to 20% respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Ciprofloxacin</content>
                        </paragraph>
                        <paragraph>Developmental toxicology studies have been performed with ciprofloxacin in rats, mice, and rabbits. The doses used in these studies are, at a minimum, approximately 200 times greater than the recommended otic human dose based on body surface area. In rats and mice, oral doses up to 100 mg/kg administered during organogenesis (Gestation Days (GD), 6-17) were not associated with adverse developmental outcomes, including embryofetal toxicity or malformations. A 30 mg/kg oral dose was associated with suppression of maternal and fetal body weight gain, but fetal malformations were not observed. Intravenous administration of doses up to 20 mg/kg to pregnant rabbits was not maternally toxic and neither embryofetal toxicity nor fetal malformations were observed. To mitigate maternal toxicity in these studies, groups of rabbits received ciprofloxacin for a different 5 day dosing period covering organogenesis (GD 6-18).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Dexamethasone</content>
                        </paragraph>
                        <paragraph>Dexamethasone has been shown to be teratogenic in mice and rabbits following topical ophthalmic application. In a rat oral developmental toxicity study, no adverse effects were observed at 0.01 mg/kg/day (0.1 times the ROHD based on BSA), although embryotoxicity was observed at higher doses.</paragraph>
                     </text>
                     <effectiveTime value="20231101"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.2">
                     <id root="2fd20f90-8706-f0d4-e063-6394a90aae9e"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>It is not known whether ciprofloxacin and dexamethasone are present in human milk following topical otic administration.</paragraph>
                        <paragraph>Published literature reports the presence of ciprofloxacin in human milk after oral administration to lactating women. However, because of the minimal systemic absorption of ciprofloxacin following topical otic administration of ciprofloxacin 0.3% and dexamethasone 0.1%otic suspension, breastfeeding is not expected to result in the exposure of the infant to ciprofloxacin
 
  <content styleCode="italics">[see Clinical Pharmacology (12.3)]</content>.

 </paragraph>
                        <paragraph>Systemically administered corticosteroids appear in human milk. Dexamethasone in breast milk could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. However, it is not known whether topical otic administration of ciprofloxacin0.3% and dexamethasone 0.1% otic suspension could result in systemic absorption that is sufficient to produce detectable quantities of dexamethasone in human milk.</paragraph>
                        <paragraph>There are no data on the effects of ciprofloxacin or dexamethasone on milk production.</paragraph>
                        <paragraph>The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension and any potential adverse effects on the breast-fed child from ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension.</paragraph>
                     </text>
                     <effectiveTime value="20231101"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="2fd20f90-8707-f0d4-e063-6394a90aae9e"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and efficacy of ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension have been established in pediatric patients 6 months and older (537 patients) in adequate and well-controlled clinical trials.</paragraph>
                        <paragraph>No clinically relevant changes in hearing function were observed in 69 pediatric patients (age 4 to 12 years) treated with ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension and tested for audiometric parameters.</paragraph>
                     </text>
                     <effectiveTime value="20231101"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="2fd20f90-8708-f0d4-e063-6394a90aae9e"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Due to the characteristics of this preparation, no toxic effects are to be expected with an otic overdose of this product.</paragraph>
               </text>
               <effectiveTime value="20231101"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="2fd20f90-8709-f0d4-e063-6394a90aae9e"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Ciprofloxacin 0.3% and dexamethasone 0.1% sterile otic suspension, USP, contains the quinolone antimicrobial, ciprofloxacin hydrochloride USP, combined with the corticosteroid, dexamethasone USP, in a sterile, preserved suspension for otic use. Each mL of ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension contains ciprofloxacin hydrochloride, USP (equivalent to 3 mg ciprofloxacin base), 1 mg dexamethasone USP, and 0.1 mg benzalkonium chloride as a preservative. The inactive ingredients are acetic acid, boric acid, edetate disodium, hydroxyethyl cellulose, water for injection, sodium acetate, sodium chloride, and tyloxapol. Sodium hydroxide or hydrochloric acid may be added for adjustment of pH.</paragraph>
                  <paragraph/>
                  <paragraph>Ciprofloxacin, a quinolone antimicrobial is available as the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid. The molecular formula is C
 
  <sub>17</sub>H
 
  <sub>18</sub>FN
 
  <sub>3</sub>O
 
  <sub>3</sub>•HCl•H
 
  <sub>2</sub>O. The molecular weight is 385.82 g/mol and the structural formula is: 
  <br/>
                     <renderMultiMedia referencedObject="img_092cb616-ce01-0716-e063-6394a90af52a"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 1: Structure of Ciprofloxacin</content>
                  </paragraph>
                  <paragraph>Dexamethasone, 9-fluoro-11(beta),17,21-trihydroxy-16(alpha)-methylpregna-1,4-diene-3,20-dione, is a corticosteroid. The molecular formula is C
 
  <sub>22</sub>H
 
  <sub>29</sub>FO
 
  <sub>5</sub>. The molecular weight is 392.46 g/mol and the structural formula is: 
  <br/>
                     <renderMultiMedia referencedObject="img_092cb758-9496-0a7a-e063-6394a90a47e3"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 2: Structure of Dexamethasone</content>
                  </paragraph>
               </text>
               <effectiveTime value="20231101"/>
               <component>
                  <observationMedia ID="img_092cb616-ce01-0716-e063-6394a90af52a">
                     <text>Cipro Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="spl-ciprofloxacin-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_092cb758-9496-0a7a-e063-6394a90a47e3">
                     <text>Dexa Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="spl-dexamethasone-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="2fd20f90-870a-f0d4-e063-6394a90aae9e"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20231101"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="2fd20f90-870b-f0d4-e063-6394a90aae9e"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Ciprofloxacin is a fluoroquinolone antibacterial
 
  <content styleCode="italics">[see Microbiology (12.4)].</content>
                        </paragraph>
                        <paragraph>Dexamethasone, a corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage and migration of inflammatory cells.</paragraph>
                     </text>
                     <effectiveTime value="20231101"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.3">
                     <id root="2fd20f90-870c-f0d4-e063-6394a90aae9e"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Following a single bilateral 4-drop (total dose = 0.28 mL, 0.84 mg ciprofloxacin, 0.28 mg dexamethasone) topical otic dose of ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension to pediatric patients, measurable plasma concentrations of ciprofloxacin and dexamethasone were observed at 6 hours following administration in 2 of 9 patients and 5 of 9 patients, respectively.</paragraph>
                        <paragraph>Mean ± SD peak plasma concentrations of ciprofloxacin were 1.39 ± 0.880 ng/mL (n = 9). Peak plasma concentrations ranged from 0.543 ng/mL to 3.45 ng/mL and were on average approximately 0.1% of peak plasma concentrations achieved with an oral dose of 250-mg. Peak plasma concentrations of ciprofloxacin were observed within 15 minutes to 2 hours post dose application.</paragraph>
                        <paragraph>Mean ± SD peak plasma concentrations of dexamethasone were 1.14 ± 1.54 ng/mL (n = 9). Peak plasma concentrations ranged from 0.135 ng/mL to 5.10 ng/mL and were on average approximately 14% of peak concentrations reported in the literature following an oral 0.5-mg tablet dose. Peak plasma concentrations of dexamethasone were observed within 15 minutes to 2 hours post dose application.</paragraph>
                        <paragraph>Dexamethasone has been added to aid in the resolution of the inflammatory response accompanying bacterial infection.</paragraph>
                     </text>
                     <effectiveTime value="20231101"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.4">
                     <id root="2fd20f90-870d-f0d4-e063-6394a90aae9e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.4 Microbiology</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Mechanism of Action</content>
                        </paragraph>
                        <paragraph>The bactericidal action of ciprofloxacin results from interference with the enzyme, DNA gyrase, which is needed for the synthesis of bacterial DNA.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Resistance</content>
                        </paragraph>
                        <paragraph>Cross-resistance has been observed between ciprofloxacin and other fluoroquinolones. There is generally no cross-resistance between ciprofloxacin and other classes of anti-bacterial agents such as beta-lactams or aminoglycosides.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Antimicrobial Activity</content>
                        </paragraph>
                        <paragraph>Ciprofloxacin has been shown to be active against most isolates of the following microorganisms, both
 
  <content styleCode="italics">in vitro</content>and clinically in otic infections
 
  <content styleCode="italics">[see Indications and Usage (1)].</content>
                        </paragraph>
                        <paragraph>Aerobic Bacteria</paragraph>
                        <paragraph>Gram-positive Bacteria</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Staphylococcus aureus</content>
                           </item>
                        </list>
                        <paragraph>Gram-negative Bacteria</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Pseudomonas aeruginosa</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20231101"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="2fd20f90-870e-f0d4-e063-6394a90aae9e"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20231101"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="2fd20f90-870f-f0d4-e063-6394a90aae9e"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>Long-term carcinogenicity studies in mice and rats have been completed for ciprofloxacin. After daily oral doses of 750 mg/kg (mice) and 250 mg/kg (rats) were administered for up to 2 years, there was no evidence that ciprofloxacin had any carcinogenic or tumorigenic effects in these species. No long-term studies of ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension have been performed to evaluate carcinogenic potential.</paragraph>
                        <paragraph>Long-term studies have not been performed to evaluate the carcinogenic potential of topical otic dexamethasone.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Eight
 
  <content styleCode="italics">in vitro</content>mutagenicity tests have been conducted with ciprofloxacin, and the test results are listed below:

 </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Salmonella</content>/Microsome Test (Negative)
 
  </item>
                           <item>
                              <content styleCode="italics">E. coli</content>DNA Repair Assay (Negative)
 
  </item>
                           <item>Mouse Lymphoma Cell Forward Mutation Assay (Positive)</item>
                           <item>Chinese Hamster V79 Cell HGPRT Test (Negative)</item>
                           <item>Syrian Hamster Embryo Cell Transformation Assay (Negative)</item>
                           <item>
                              <content styleCode="italics">Saccharomyces cerevisiae</content>Point Mutation Assay (Negative)
 
  </item>
                           <item>
                              <content styleCode="italics">Saccharomyces cerevisiae</content>Mitotic Crossover and Gene Conversion Assay (Negative)
 
  </item>
                           <item>Rat Hepatocyte DNA Repair Assay (Positive)</item>
                        </list>
                        <paragraph>Thus, 2 of the 8 tests were positive, but results of the following 3
 
  <content styleCode="italics">in vivo</content>test systems gave negative results:

 </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Rat Hepatocyte DNA Repair Assay</item>
                           <item>Micronucleus Test (Mice)</item>
                           <item>Dominant Lethal Test (Mice)</item>
                        </list>
                        <paragraph>Dexamethasone has been tested for
 
  <content styleCode="italics">in vitro</content>and
 
  <content styleCode="italics">in vivo</content>genotoxic potential and shown to be positive in the following assays: chromosomal aberrations, sister-chromatid exchange in human lymphocytes, and micronuclei and sister-chromatid exchanges in mouse bone marrow. However, the Ames/Salmonella assay, both with and without S9 mix, did not show any increase in His+ revertants.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Fertility studies performed in male and female rats at oral doses of ciprofloxacin up to 100 mg/kg (approximately 482 times the ROHD of ciprofloxacin based on BSA) revealed no evidence of impairment. Male rats received oral ciprofloxacin for 10 weeks prior to mating and females were dosed for 3 weeks prior to mating through GD 7.</paragraph>
                        <paragraph>The effect of dexamethasone on fertility has not been investigated following topical otic application. However, the lowest toxic dose of dexamethasone identified following topical dermal application was 1.802 mg/kg in a 26-week study in male rats and resulted in changes to the testes, epididymis, sperm duct, prostate, seminal vesicle, Cowper's gland, and accessory glands. The relevance of this study for short-term topical otic use is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20231101"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_13.2">
                     <id root="2fd20f90-8710-f0d4-e063-6394a90aae9e"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Pharmacology and/ OR Toxicology</title>
                     <text>
                        <paragraph>Guinea pigs dosed in the middle ear with ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension for one month exhibited no drug-related structural or functional changes of the cochlear hair cells and no lesions in the ossicles.</paragraph>
                     </text>
                     <effectiveTime value="20231101"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_14">
               <id root="2fd20f90-8711-f0d4-e063-6394a90aae9e"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>In 2 randomized multicenter, controlled clinical trials, ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension dosed 2 times per day for 7 days demonstrated clinical cures in 87% and 94% of per protocol evaluable AOE patients, respectively, compared to 84% and 89%, respectively, for otic suspension containing neomycin 0.35%, polymyxin B 10,000 units/mL, and hydrocortisone 1.0% (neo/poly/HC). Among culture positive patients clinical cures were 86% and 92% for ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension compared to 84% and 89%, respectively, for neo/poly/HC. Microbiological eradication rates for these patients in the same clinical trials were 86% and 92% for ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension compared to 85% and 85%, respectively, for neo/poly/HC.</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20231101"/>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="2fd20f90-8712-f0d4-e063-6394a90aae9e"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">How Supplied:</content>
                  </paragraph>
                  <paragraph>Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension, USP is a white-to off-white suspension supplied as follows: 7.5 mL fill in a system consisting of a natural polyethylene bottle and natural plug, with a white HDPE closure. Tamper evidence is provided with a tamper-evident ring around the closure and neck area of the package. </paragraph>
                  <paragraph>NDC 72485-625-13       7.5 mL fill</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Storage: </content>Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

 </paragraph>
                  <paragraph>Avoid freezing. Protect from light.</paragraph>
               </text>
               <effectiveTime value="20231101"/>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="2fd20f90-8713-f0d4-e063-6394a90aae9e"/>
               <code code="88436-1" codeSystem="2.16.840.1.113883.6.1" displayName="PATIENT COUNSELING INFORMATION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).</paragraph>
                  <paragraph>
                     <content styleCode="underline">For Otic Use Only</content>
                  </paragraph>
                  <paragraph>Advise patients that ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension is for
 
  <content styleCode="bold">otic use (ears) only. This product must not be used in the eye</content>
                     <content styleCode="italics">[see Dosage and Administration (2.2)]</content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Administration Instructions</content>
                  </paragraph>
                  <paragraph>Instruct patients to warm the bottle in their hand for one to two minutes prior to use and shake well immediately before using
 
  <content styleCode="italics">[see Dosage and Administration (2.1, 2.2)]</content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Allergic Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients to discontinue use immediately and contact their physician, if rash or allergic reaction occurs
 
  <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Avoid Contamination of the Product</content>
                  </paragraph>
                  <paragraph>Advise patients to avoid contaminating the tip with material from the ear, fingers, or other sources
 
  <content styleCode="italics">[see Instructions for Use].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Duration of Use</content>
                  </paragraph>
                  <paragraph>Advise patients that it is very important to use the eardrops for as long as their doctor has instructed, even if the symptoms improve
 
  <content styleCode="italics">[see Patient Information]</content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Protect from Light</content>
                  </paragraph>
                  <paragraph>Advise patients to protect the product from light
 
  <content styleCode="italics">[see How Supplied/Storage and Handling (16)]</content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Unused Product</content>
                  </paragraph>
                  <paragraph>Advise patients to discard unused portion after therapy is completed
 
  <content styleCode="italics">[see Dosage and Administration (2.2)]</content>.

 </paragraph>
                  <paragraph>Distributed by: Armas Pharmceuticals, Inc.</paragraph>
                  <paragraph>Freehold, NJ 07728 USA</paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>Ophtapharm AG Riethofstrasse 1, Hettlingen, 8442,</paragraph>
                  <paragraph>Switzerland (CHE) for Sentiss</paragraph>
                  <paragraph>Made in Switzerland                               Rev. 08/23</paragraph>
               </text>
               <effectiveTime value="20231101"/>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_9">
               <id root="2fd20f90-8714-f0d4-e063-6394a90aae9e"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>PATIENT INFORMATION</title>
               <text>
                  <table cellpadding="0" cellspacing="0" width="684.684px">
                     <col width="50.6118881118881%"/>
                     <col width="49.3881118881119%"/>
                     <tbody>
                        <tr styleCode="Botrule First">
                           <td align="center" colspan="2" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">PATIENT INFORMATION</content>
                              <br/>
                              <content styleCode="bold">Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" colspan="2" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">What is ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension?</content>
                              <br/>  Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension is a prescription medicine used in the ear only (otic use) that contains 2 medicines, a quinolone antibiotic medicine called ciprofloxacin and a corticosteroid medicine called dexamethasone. Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension is used in adults and children 6 months of age or older to treat certain types of infections caused by certain germs called bacteria. These bacterial infections include:
    
     <list listType="unordered" styleCode="Disc">
                                 <item>outer ear canal infection (known as acute otitis externa or AOE)</item>
                              </list>It is not known if ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension is safe and effective in children under 6 months of age.
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" colspan="2" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">Who should not use ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension?</content>
                              <br/>
                              <content styleCode="bold">Do not use ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension if you:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>are allergic to ciprofloxacin, quinolones, or any of the ingredients in ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension. See the end of this Patient Information leaflet for a complete list of ingredients in ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension.</item>
                                 <item>have an outer ear canal infection caused by certain viruses, including the herpes simplex virus.</item>
                                 <item>have an ear infection caused by a fungus.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" colspan="2" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">What should I tell my doctor before using ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension?</content>
                              <br/>
                              <content styleCode="bold">Before using ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension, tell your doctor about all of your medical conditions, including if you:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>are pregnant or plan to become pregnant. It is not known if ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension will harm your unborn baby.</item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension passes into your breast milk. Talk to your doctor about the best way to feed your baby during treatment with ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension.</item>
                              </list>Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" colspan="2" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">How should I use ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Read the detailed
      
       <content styleCode="bold">Instructions for Use</content>that come with ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension.
     
      </item>
                                 <item>Use ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension exactly as your doctor tells you to.</item>
                                 <item>
                                    <content styleCode="bold">Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension is for use in the ear only (otic use)</content>
                                    <content styleCode="bold">. Do not use ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension in the eye or inject ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension.</content>
                                 </item>
                                 <item>Apply 4 drops of ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension into the affected ear 2 times a day for 7 days.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content>stop using ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension unless your doctor tells you to, even if your symptoms improve.
     
      </item>
                              </list>If your symptoms do not improve after 7 days of treatment with ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension, call your doctor.
    
     <list listType="unordered" styleCode="Disc">
                                 <item>Call your doctor right away if:
      
       <list listType="unordered" styleCode="Disc">
                                       <item>you have fluid that continues to drain from your ear (otorrhea) after you have finished your treatment with ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension</item>
                                       <item>you have fluid that drains from your ear
        
         <content styleCode="bold">2 or more times within 6 months</content>after you stop treatment with ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension
       
        </item>
                                    </list>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" colspan="2" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">What are the possible side effects of ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension? Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension may cause serious side effects, including:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">allergic reactions</content>. Stop using ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension and call your doctor or go to the nearest emergency room if you have any of the following signs or symptoms of an allergic reaction:
      
       <list listType="unordered" styleCode="Disc">
                                       <item>hives (urticaria)</item>
                                       <item>trouble breathing</item>
                                       <item>swelling of your face, lips, mouth, or tongue</item>
                                       <item>dizziness, fast heartbeat, or pounding in your chest</item>
                                       <item>rash</item>
                                       <item>itching</item>
                                    </list>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" colspan="2" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">The most common side effects of ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension include:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>ear discomfort</item>
                                 <item>ear pain</item>
                                 <item>ear itching (pruritus)</item>
                              </list>These are not all the possible side effects of ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" colspan="2" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">How should I store ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension at room temperature between 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F)</item>
                                 <item>Do not freeze ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension.</item>
                                 <item>Keep ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension out of light.</item>
                              </list>
                              <content styleCode="bold">Keep ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" colspan="2" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">General information about the safe and effective use of ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension.</content>
                              <br/>  Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.
    
     <content styleCode="bold">Do not use ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension for a condition for which it was not prescribed.</content>Do not give ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or doctor for information about ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension that is written for health professionals.
   
    </td>
                        </tr>
                        <tr>
                           <td align="justify" colspan="2" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">What are the ingredients in ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension?</content>
                              <br/>
                              <content styleCode="bold">Active ingredients:</content>ciprofloxacin hydrochloride USP, dexamethasone USP, and benzalkonium chloride as a preservative 
     <br/>
                              <content styleCode="bold">Inactive ingredients:</content>acetic acid, boric acid, edetate disodium, hydroxyethyl cellulose, water for injection, sodium acetate, sodium chloride, and tyloxapol. Sodium hydroxide or hydrochloric acid may be added for adjustment of pH. 
     <br/>  Distributed by: Armas Pharmceuticals, Inc.
    
     <paragraph>Freehold, NJ 07728 USA</paragraph>
                              <paragraph>Manufactured by:</paragraph>
                              <paragraph>Ophtapharm AG Riethofstrasse 1, Hettlingen, 8442,</paragraph>
                              <paragraph>Switzerland (CHE) for Sentiss</paragraph>
                              <paragraph>Made in Switzerland Rev. 08/23</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration Revised: August 2023</paragraph>
               </text>
               <effectiveTime value="20231101"/>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_10">
               <id root="2fd20f90-8715-f0d4-e063-6394a90aae9e"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>INSTRUCTIONS FOR USE</title>
               <text>
                  <table cellpadding="0" cellspacing="0" width="684.684">
                     <col width="100%"/>
                     <tbody>
                        <tr styleCode="Botrule First">
                           <td align="center" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                              <br/>
                              <content styleCode="bold">Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension</content>
                              <br/>
                              <content styleCode="bold">This “Instructions for Use” contains information on how to use ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension.</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">Important Information You Need to Know Before Using ciprofloxacin 0.3% and dexamethasone 0.1%</content>
                              <content styleCode="bold">otic suspension.</content>
                              <br/>
                              <br/>  Read this Instructions for Use that comes with ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension before you start using it and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or treatment.
    
     <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Use ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension exactly as your doctor tells you to use it.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension is for use in the ear only (otic use)</content>. Do not inject ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension or use ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension in the eye.
     
      </item>
                                 <item>
                                    <content styleCode="bold">Shake ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension well before each use</content>.
     
      </item>
                                 <item>
                                    <content styleCode="bold">Do not touch your ear, fingers, or other surfaces with the tip of the ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension bottle</content>. You may get bacteria on the tip of the bottle that can cause you to get another infection.
     
      </item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" styleCode="Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">How should I use ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension?</content>
                                 <br/>
                                 <content styleCode="bold">Step 1.</content>Wash your hands with soap and water (see
     
      <content styleCode="bold">Figure A</content>).
    
     </paragraph>
                              <paragraph>
                                 <br/>
                                 <content styleCode="bold">Figure A</content>
                              </paragraph>
                              <paragraph>
                                 <renderMultiMedia referencedObject="img_092cb758-9497-0a7a-e063-6394a90a47e3"/>
                                 <br/>
                                 <content styleCode="bold">Step 2.</content>Warm the bottle of ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension by
     
      <content styleCode="bold">rolling the bottle between your hands for 1 to 2 minutes</content>(see
     
      <content styleCode="bold">Figure B)</content>. Shake the bottle of ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension well. 
      <br/>
                                 <br/>
                                 <content styleCode="bold">Figure B</content>
                              </paragraph>
                              <paragraph>
                                 <renderMultiMedia referencedObject="img_092ca740-a06a-0585-e063-6394a90a3439"/>
                              </paragraph>
                              <paragraph>
                                 <br/>
                                 <content styleCode="bold">Step 3.</content>Remove the ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension cap. Put the cap in a clean and dry area.
     
      <content styleCode="bold">Do not</content>let the tip of the bottle touch your ear, fingers or other surfaces. 
      <br/>
                                 <content styleCode="bold">Step 4</content>. Lie down on your side so that the affected ear faces upward (see
     
      <content styleCode="bold">Figure C</content>). 
      <br/>
                                 <br/>
                                 <content styleCode="bold">Figure C</content>
                                 <br/>
                                 <renderMultiMedia referencedObject="img_092cb616-ce05-0716-e063-6394a90af52a"/>
                                 <br/>
                                 <content styleCode="bold">Step 5</content>. Hold the bottle of ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension between your thumb and index finger (see
     
      <content styleCode="bold">Figure D</content>). Place the tip of the bottle close to your ear.
     
      <content styleCode="bold">Be careful not to touch your fingers or ear with the tip of the bottle</content>.
    
     </paragraph>
                              <paragraph>
                                 <br/>
                                 <content styleCode="bold">Figure D</content>
                                 <br/>
                                 <renderMultiMedia referencedObject="img_092cc174-7169-10db-e063-6394a90a3c3f"/>
                                 <br/>
                                 <content styleCode="bold">Step 6</content>. Gently squeeze the bottle and let 4 drops of ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension fall into the affected ear. If a drop misses your ear, follow the instructions in Step 5 again. 
      <br/>
                                 <br/>
                                 <content styleCode="bold">Step 7. Stay on your side</content>with the affected ear facing upward (see
     
      <content styleCode="bold">Figure C).</content>
                                 <br/>
                                 <content styleCode="bold">It is important that you follow the instructions below for your specific ear infection,</content>to allow ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension to enter the affected part of your ear. 
      <br/>
                                 <content styleCode="bold">Step 8</content>. 
      <br/>  If you use ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension to treat an
     
      <content styleCode="bold">outer ear canal infection</content>:
    
     </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Gently pull the outer ear lobe upward and backward (see
      
       <content styleCode="bold">Figure E</content>). This will allow the drops of ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension to enter your ear canal.
     
      </item>
                                 <item>Remain on your side with the affected ear facing upward (see
      
       <content styleCode="bold">Figure C</content>) for 1 minute.
     
      </item>
                              </list>
                              <content styleCode="bold">Figure E</content>
                              <br/>
                              <renderMultiMedia referencedObject="img_092ca740-a06b-0585-e063-6394a90a3439"/>
                              <br/>
                              <br/>
                              <content styleCode="bold">Step 9</content>. If your doctor has told you to use ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension in both ears, repeat steps 5 to 8 for your other ear. 
     <br/>
                              <br/>
                              <content styleCode="bold">Step 10</content>. Put the cap back on the bottle and close it tightly. 
     <br/>
                              <br/>
                              <content styleCode="bold">Step 11</content>. After you have used all of your ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension doses, there may be some ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension left in the bottle. Throw the bottle away.
   
    </td>
                        </tr>
                        <tr>
                           <td align="justify" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">How should I store ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension at 20° to 25°C (68° to 77°F).</item>
                                 <item>Do not freeze ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension.</item>
                                 <item>Keep ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension out of light.</item>
                              </list>
                              <br/>
                              <content styleCode="bold">Keep ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension and all medicines out of the reach of children.</content>
                              <br/>
                              <br/>  If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for more information about ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension that is written for health professionals. 
     <br/>
                              <br/>  Distributed by: Armas Pharmceuticals, Inc. 
     <br/>  Freehold, NJ 07728 USA
    
     <paragraph>Manufactured by:</paragraph>
                              <paragraph>Ophtapharm AG Riethofstrasse 1, Hettlingen, 8442,</paragraph>
                              <paragraph>Switzerland (CHE) for Sentiss</paragraph>
                              <paragraph>Made in Switzerland Rev. 08/23</paragraph>
                              <paragraph/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration. Revised: August 2023</paragraph>
               </text>
               <effectiveTime value="20231101"/>
               <component>
                  <observationMedia ID="img_092cb758-9497-0a7a-e063-6394a90a47e3">
                     <text>Figure A</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="spl-ifu-fig-a.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_092ca740-a06a-0585-e063-6394a90a3439">
                     <text>Figure B</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="spl-figure-A.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_092cb616-ce05-0716-e063-6394a90af52a">
                     <text>Figure C</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="spl-figure-B.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_092cc174-7169-10db-e063-6394a90a3c3f">
                     <text>Figure D</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="spl-figure-C.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_092ca740-a06b-0585-e063-6394a90a3439">
                     <text>Figure E</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="spl-figure-E.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_18">
               <id root="2fd20f90-8716-f0d4-e063-6394a90aae9e"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL-Label</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 72485-625-13 
   <br/>  Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension USP 
   <br/>  FOR TOPICAL USE IN THE EAR ONLY.
  </content>Rx only 
  <br/>  7.5 mL

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_092c9e31-7c44-f29b-e063-6394a90a9da6"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20231101"/>
               <component>
                  <observationMedia ID="img_092c9e31-7c44-f29b-e063-6394a90a9da6">
                     <text>Container Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="ciprodex 7.5 ml container label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_21">
               <id root="2fd20f90-8717-f0d4-e063-6394a90aae9e"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL-Showbox</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 72485-625-13 
   <br/>  Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension USP 
   <br/>  FOR TOPICAL USE IN THE EAR ONLY.
  </content>Rx only 
  <br/>  7.5 mL 
  <br/>  Sterile

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_092ca3ca-a351-0583-e063-6394a90a3ee1"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20231101"/>
               <component>
                  <observationMedia ID="img_092ca3ca-a351-0583-e063-6394a90a3ee1">
                     <text>Carton Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="ciprodex 7.5 ml carton label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>